4 days ago4 minRevive Announces Research Collaboration with North Carolina State University for....The biosynthetic platform provides a potential simple and efficient method for rapidly producing natural
Dec 23, 20207 minRevive Update on Phase 3, COVID19 Clinical Trial with Bucillamine - Plans on Emergency Use Access..The Company’s clinical safety team has actively monitored ongoing interim data of patients and found there have been no safety concerns.....
Dec 21, 20204 minRevive Therapeutics Announces LOI to Acquire PharmaTher’s Psilocybin ProgramThe final terms will be agreed to by the parties after the completion of due diligence by Revive - Expected to close on or before Jan.31.21
Dec 15, 20206 minLiquid Avatar Partners with XTM to Verify COVID-19 Vaccination Verifiable CredentialsLiquid Avatar Partners with Fintech Innovator XTM to enable Hospitality, Personal Care and other Sectors to Verify COVID19 Vaccine....
Dec 8, 202011 minLiquid Avatar, Lumedic, Loop Insights, The Campus Agency and TripXpertz Form Consortium to Manage...Liquid Avatar, Lumedic, Loop Insights, The Campus Agency and TripXpertz Form Consortium to Manage Verifiable Identity Credentials for COV...
Oct 14, 20203 minAlgernon Pharmaceuticals Announces 25% Enrollment in its Ifenprodil IPF and Chronic Cough Phase 2...Algernon has reached 25% of its enrollment target for its Phase 2 idiopathic pulmonary fibrosis (IPF) and chronic cough clinical study...
Sep 29, 20204 minAlgernon Announces Enrollment of 100 Patients in 2b/3 Human Study for Treatment of COVID-19Algernon is pleased to announce that it has now enrolled 100 patients, which is two thirds of it enrollment target...
Sep 29, 20205 minRevive Therapeutics Announces Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19The Company has selected and finalized with five clinical sites in Florida, Texas and California for enrollment of patients in the Phase 3..
Sep 22, 20204 minAlgernon Announces 50% Enrollment in Multinational 2b/3 Human Study for Treatment of COVID-19Algernon has now enrolled 75 patients, which is 50% of its enrollment target, for its multinational Phase 2b/3 human study of NP-120
Sep 16, 20205 minRevive Announces IRB Approval of US Expanded Access Treatment Program for Bucillamine in COVID-19Revive Therapeutics Announces IRB Approval of US Expanded Access Treatment Program (Compassionate Use) for Bucillamine in COVID-19